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Introduction. Brachytherapy as a boost in breast cancer, after conservative surgery and whole breast external beam radiotherapy
is a well known and accepted type of treatment. Traditionally in breast brachytherapy the dose used to be prescribed over the
basal points, following the paris system in a theoretical dosimetry. Nowadays, 3D planiﬁcation systems have been incorporated,
so the PTV can be delineated on the CT-scan . Dosimetric and dose distribution differences can be found between the two types
of planiﬁcation.
Purpose. To evaluate the different dose distributions between the prescription over the basal points and the prescription over the
PTV points.
Materials and methods. We analyze 6 patients 3D brachytherapy dosimetries, and in every case we compare the dose, prescribing
over the basal points and prescribing over the PTV points, determining in every type of planiﬁcation the V150, V200 and D90.
Results. When the dose is prescribed over the PTV points, D90 is higher tan when the dose is prescribed over the basal points in
every patient. V150 and V200 are also higher when the dose is prescribed over the PTV points, but in any case the V200 exceeds
10 cm3, and any case V150 exceeds 15 cm3.
Conclusions. When a 3D CT-scan planiﬁcation is done, prescribing over the PTV obtains a better covering of the target and does
not exceed the limits of the high dose RTOG recommendations.
http://dx.doi.org/10.1016/j.rpor.2013.03.020
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Patients and method. A male 58 year old patient, with a history of primary carcinoma of the trachea T2N1M0 large cell, treated with
chemotherapy and radical radiotherapy in 2007 and intratracheal stent of Poliﬂex. In 2009, was made a periprosthetic accurate
resection of granulomas in the proximal and distal area and mitomycin C locally application. In June 2011 it was operated
to partial breakage of the prosthesis, it not being removable. In the June 2012, objective excrescencies mucosal lesions in the
bronchial tree left in separation carina LSI with LII, suggestive of carcinoma in situ it was seen on ﬁbrobronchoscopy. Pathology
microinvasive squamous carcinoma, with areas of carcinoma in situ. It was made an extension’s study and it was classify as
T1N0M0. Given the characteristics of the patient and tracheal tumor prior radiotherapy and salvage surgery impossible, primary
radical brachytherapy treatment was decided.
Results. It has been calculated the doses received for the treatment of the tracheal tumor, that has been of 1230 cGy, in the
zone currently affects It has been programmed 4 or 5 sessions of endobronchial brachytherapy with high rate of doses with the
team VarisourceTM unit and punctual source of 0.5 cm of I-131, around the affected areas, making the collocation of the plastic
endobronchial catheter of VARIAN of 4.7 Fr and 150 cm, simulation TAC in situ and dosimetric calculation with application of the
session right after, previous displacement of the patient from the TAC’s room, with mobile table, to the brachytherapy’s bunker.
It was applied initially 4 sessions of 5Gy with calculation at 10mm from the central axis of the radioactive source and 5 cm
active length. The lesion measured approximately 2.5 cm and it was left one centimeter of margin inside the axial axis. In the 4◦
session it was objectiﬁed a macroscopic disappearance of the lesion and it was given a 5◦ session of consolidation, receiving in
total 25Gy with interval between sessions from 1 to 2 weeks. In the 5◦ session it was taken a biopsy of the erythematosis area
and it was conﬁrm in anatomapatological inform the absence of illness.
Conclusion. The primary radical brachytherapy is a feasible treatment and that can be offered in patients without no other
alternatives and incipient lesions.
http://dx.doi.org/10.1016/j.rpor.2013.03.021
Exclusive brachytherapy in intermediate risk prostate cancer
I. Linares Galiana, M. Martínez Carrillo, M. Gentil Jiménez, M. Vargas Arrabal, M. Guerrero Tejada
Hospital Universitario Virgen de Las Nieves, Oncología Radioterápica, Spain
Objective. Intermediate risk patients of prostate cancer are a heterogeneous subgroup, since the probability to develop extrapro-
static disease is variable. The treatment of choice is the combination of conformal radiotherapy (CRT) +Brachytherapy but there
are some patients who may beneﬁt from exclusive brachytherapy.
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Material and methods. Patient of 59 years with no history of interest, which is detected in routine screening PSA elevation (8.3ng).
Biopsy: Gleason 3+4 adenocarcinoma (ADC) in 2/3 cylinders right lobe; left lobe (0/3). Prostate volume 25 cm3. Maximum ﬂowme-
try: 22.2ml/s. IPSS: 5. QLQ PR 25: 10 Urinary Incontinence 1, Intestinal 4, Sexual Activity 5, Functionality 8. Negative extension
study. ADC is diagnosed as intermediate risk prostate D’Amico groups say (cT1c). The patient refused surgery for what is referred
to our department to evaluate alternative healing less morbidity. Radiotherapy toyed three options: exclusive Brachytherapy
vs Brachytherapy+CRT vs CRT+short-term androgen deprivation. We opted for exclusive Brachytherapy being shorter treat-
ment which provides reduced toxicity. It makes permanent implant prostate Brachytherapy with I-125 seeds for a dose of PTV
(prostate +margin 5mm) of 145Gy.
Results. At the ﬁrst month post-Brachytherapy PSA levels reached 9.64ng/ml. At 6 months, the PSA down to 3.37 and the score
on the QLQ PR 25 shows an improvement in urinary symptoms and asymptomatic from the standpoint of bowel and sexual. At
12 months is detected PSA nadir (0.9ng/ml).
Conclusion. Intermediate risk patients are candidates mostly combined treatment (CRT+Brachytherapy), but there is a selected
subgroup, in which 100% of experts consulted agree deal with alone Brachytherapy: absence of perineural invasion, cT1c, <30%
cylinders (+) in the biopsy, Gleason 7 (3 + 4) or PSA 10–20ng/ml, obtaining a good control of the diseasewithout providing excessive
toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.022
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Introduction. The prostate cancer is the most frequent tumor in men; the radiotherapy and brachytherapy are an alternative
treatment highly effective and tolerable. In May of 2011 we have developed LDR brachytherapy technique in our unit, indicated
for low risk prostate cancer patients.
Objectives. To analyze the results in our experience by dosimetric parameters and acute toxicity and comparing with our previous
studies with HDR exclusive brachytherapy.
Material and methods. An observational retrospective study has been realized reviewing the dosimetric and clinics parameters of
44 low risk prostate cancer patients treated with LDR brachytherapy between May of 2011 and December of 2012.
Results. The mean age is 70 years (48–82). The dose administrated was 145Gy I-125. Dosimetric parameters: Prostate (V100: 96.4%,
D90: 114% y V150: 50%), urethra (D1%<160, D10%>150% y D30%>130%) and rectum (D2cc<145Gy y D1cc<160Gy). The treatment
tolerance was acceptable with those results on acute toxicity: dysuria 27.3%, pollakiuria 9%, strangury 25%, urgency 6.8%, acute
urinary retention 2.3%, urinary incontinence 6.8% and proctitis 4.5%. In HDR brachytherapy: The mean age is 71 years (50–79)
who received 34–36Gy in 4 fractions. Dysuria 18%, urgency 6.2%, acute urinary retention 15%, urinary incontinence 6.8% and
proctitis 5%, as acute toxicity.
Conclusions. The LDR brachytherapy is a good option for low risk prostate cancer treatment, based on the dosimetric parameters
and acute toxicity observed, like HDR, highlighting a decreased in acute urinary retention and urinary incontinence. We need
continue monitoring these patients and increased the number of patients included to reach more conclusions.
http://dx.doi.org/10.1016/j.rpor.2013.03.023
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Introduction. Patients with intermediate risk prostate neoplasms have been treated using ERBT plus radioactive implants Iodine
125 (LDR) to improve local control.
Material and methods. From 2004 to 2012, 99 ERBT plus LDR implants were performed. Patients (pts) had a median age of 64 (47–76);
Mean PSA is 7.4ng/ml (4–18); Gleason distribution was G6 9 pts (9.1%), G7 85 (85.9%) G8 4 pts (4%) G9 1 pts 1(1%). Tumor stage
distribution was T1 52 pts. (52.5%), T2 45 pts (45.5%), and T3 2 pts (2%). No patients with positive nodes or metastasis were
treated. External radiation therapy was administered on the prostate, seminal vesicles and a margin of safety, at a dose of 45Gy
in 3 cases, 46Gy in 88 cases, 48Gy in 1 case and 50Gy in 7 cases. After external radiotherapy brachytherapy was administered
